Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here

Pricing and Ordering Information

 

U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Biopsy, and Tissue Screening Products
Report #A417
- January 2014
261 Pages – 38 Exhibits – 15 Company Profiles


Cancer is the second-leading cause of death in the United States (U.S.) after heart disease. It is estimated that nearly 1.7 million people in the country will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. In the fight against cancer, diagnostic ultrasound imaging, minimally invasive biopsy, and tissue screening are among the methods that allow physicians to detect malignancies at their earliest and most treatable stages.

In 2012, approximately 92.0 million oncology-related diagnostic ultrasound, minimally invasive biopsy, and tissue screening procedures were performed in the U.S. Together, these procedures generated approximately $1.1 billion in corresponding product sales; it is expected that during the forecast period covered by this report, sales of diagnostic ultrasound, minimally invasive biopsy, and tissue screening products for oncology-related indications will increase at a compound annual rate of 3.9%, reaching nearly $1.4 billion in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.

Covered topics in this report include an overview of cancer in the U.S. including discussions of the different forms of the disease; automated and semi-automated tissue screening technologies; capacitive micromachined ultrasonic transducers; contrast-enhanced ultrasound; core needle biopsy systems; diagnostic ultrasound systems; Doppler and tissue harmonic imaging; fine-needle aspiration; human papilloma virus testing systems; minimally invasive biopsy; Papanicolaou smear testing systems; photoacoustic imaging; risk factors for cancer development; statistics covering new cancer cases, cancer prevalence, and cancer-related deaths; tissue elastography; and vacuum-assisted biopsy systems; among others

Ordering Information

Title

Report# Publication
Date
List Price

U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Biopsy, and Tissue Screening Products

A417

January 2014

$3,750

Order Online:
Single User only (Please call for corporate subscription pricing)
PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

 

i.       New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer

ii.       Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Procedures

iii.      Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products

a.      Oncology-Related Diagnostic Ultrasound Systems Market Segment

b.      Minimally Invasive Biopsy Systems Market Segment

c.      Tissue Screening Systems Market Segment

iv.         Methodology

 

Exhibit ES-1:    Estimated New Cases, Prevalence,and Deaths for Selected Types of Cancer

Exhibit ES-2:    Oncology-Related Diagnostic Ultrasound,Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017

Exhibit ES-3:    Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products, Combined Market Forecast, 2012-2017

Exhibit ES-4:    Oncology-Related Diagnostic Ultrasound Systems,  Market Forecast, 2012-2017

Exhibit ES-5:    Minimally Invasive Biopsy Products, Market Forecast, 2012-2017

Exhibit ES-6:    Tissue Screening Products, Market Forecast, 2012-2017

 

 

1. CANCER STATISTICS UPDATE

1.1 Acquired Capabilities of Cancer Cells

1.2 Cataloging Genomic Alterations Involved in the Development of Cancer

1.3 Risk Factors Associated with the Development of Cancer

1.4 Cancer Staging

1.5 New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer

1.6 Clinical and Statistical Data for Selected Types of Cancer

1.6.1 Brain and Other Nervous System Cancers

1.6.1.1 Etiology

1.6.1.2 Epidemiology

1.6.2 Breast Cancer

1.6.2.1 Etiology

1.6.2.2 Epidemiology

1.6.3 Colorectal Cancer

1.6.3.1 Etiology

1.6.3.2 Epidemiology

1.6.4 Kidney/Renal Pelvis Cancer

1.6.4.1 Etiology

1.6.4.2 Epidemiology

1.6.5 Leukemia

1.6.5.1 Etiology

1.6.5.2 Epidemiology

1.6.6 Lung/Bronchus Cancer

1.6.6.1 Etiology

1.6.6.2 Epidemiology

1.6.7 Lymphoma

1.6.7.1 Etiology

1.6.7.2 Epidemiology

1.6.8 Melanoma

1.6.8.1 Etiology

1.6.8.2 Epidemiology

1.6.9 Oral Cavity and Pharyngeal Cancers

1.6.9.1 Etiology

1.6.9.2 Epidemiology

1.6.10 Ovarian Cancer

1.6.10.1 Etiology

1.6.10.2 Epidemiology

1.6.11 Pancreatic Cancer

1.6.11.1 Etiology

1.6.11.2 Epidemiology

1.6.12 Prostate Cancer

1.6.12.1 Etiology

1.6.12.2 Epidemiology

1.6.13 Thyroid Cancer

1.6.13.1 Etiology

1.6.13.2 Epidemiology

1.6.14 Urinary Bladder Cancer

1.6.14.1 Etiology

1.6.14.2 Epidemiology

1.6.15 Uterine Cancer

1.6.15.1 Etiology

1.6.15.2 Epidemiology

 

Exhibit 1-1:      Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer

Exhibit 1-2:      Brain and Other Nervous System Cancers, Facts And Figures

Exhibit 1-3:      Breast Cancer, Facts And Figures

Exhibit 1-4:      Colorectal Cancer, Facts And Figures

Exhibit 1-5:      Kidney/Renal Pelvis Cancers, Facts And Figures

Exhibit 1-6:      Leukemia, Facts and Figures

Exhibit 1-7:      Lung/Bronchus Cancer, Facts And Figures

Exhibit 1-8:      Hodgkin Lymphoma, Facts and Figures

Exhibit 1-9:      Non-Hodgkin Lymphoma, Facts and Figures

Exhibit 1-10:    Melanoma of the Skin, Facts and Figures

Exhibit 1-11:    Oral Cavity and Pharyngeal Cancers, Facts and Figures

Exhibit 1-12:    Ovarian Cancer, Facts and Figures

Exhibit 1-13:    Pancreatic Cancer, Fact and Figures

Exhibit 1-14:    Prostate Cancer, Facts And Figures

Exhibit 1-15:    Thyroid Cancer, Fact and Figures

Exhibit 1-16:    Urinary Bladder Cancer, Fact and Figures

Exhibit 1-17:    Cancer of the Uterine Corpus, Facts and Figures

Exhibit 1-18:    Cancer of the Uterine Cervix, Facts and Figures

 

 

2. U.S. MARKETS FOR ONCOLOGY-RELATED DIAGNOSTIC ULTRASOUND, MINIMALLY INVASIVE BIOPSY, AND TISSUE SCREENING PRODUCTS

2.1 Diagnostic Ultrasound Systems, Market Analysis

2.1.1 Technologies

2.1.1.1 Doppler Imaging

2.1.1.2 Tissue Harmonic Imaging

2.1.1.3 Tissue Elastography

2.1.1.4 Contrast-Enhanced Ultrasound

2.1.2 Procedure Volumes

2.1.3 Products

2.1.4 Market Forecast

2.1.5 Competitive Analysis

2.2 Minimally Invasive Biopsy Systems, Market Analysis

2.2.1 Technologies

2.2.1.1 Core Needle/Fine Needle/Multipurpose Tool-Assisted Biopsy

2.2.1.2 Vacuum-Assisted Biopsy

2.2.2 Procedure Volumes

2.2.3 Products

2.2.4 Market Forecast

2.2.5 Competitive Analysis

2.3 Tissue Screening, Market Analysis

2.3.1 Technologies

2.3.2 Procedure Volumes

2.3.3 Products

2.3.4 Market Forecast

2.3.5 Competitive Analysis

 

Exhibit 2-1:      Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017

Exhibit 2-2:      Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products, Combined Market  Forecast, 2012-2017

Exhibit 2-3:      Oncology-Related Diagnostic Ultrasound, Procedure Volumes Forecast, 2012-2017

Exhibit 2-4:      2014, Selected Diagnostic Ultrasound Systems

Exhibit 2-5:      Oncology-Related Diagnostic Ultrasound Systems, Market Forecast, 2012-2017

Exhibit 2-6:      2012, Oncology-Related Diagnostic Ultrasound Systems Market, Share by Supplier

Exhibit 2-7:      Minimally Invasive Biopsy, Procedure Volumes Forecast, 2012-2017

Exhibit 2-8:      2014, Selected Minimally Invasive Biopsy Products

Exhibit 2-9:      Minimally Invasive Biopsy Products, Market Forecast, 2012-2017

Exhibit 2-10:    2012, Minimally Invasive Biopsy Products Market, Share by Supplier

Exhibit 2-11:    Tissue Screening, Procedure Volumes Forecast, 2012-2017

Exhibit 2-12:    2014, Selected Tissue Screening Products

Exhibit 2-13:    Tissue Screening Products, Market Forecast, 2012-2017

Exhibit 2-14:    2012, Tissue Screening Products Market, Share by Supplier

 

 

3. COMPANY PROFILES

3.1    Analogic Corporation

3.2    Bard Biopsy Systems/ Bard Peripheral Vascular, Inc./ C.R. Bard, Inc

3.3    Becton, Dickinson and Company

3.4    CareFusion Corporation

3.5    Fujifilm SonoSite, Inc./Fujifilm Medical Systems USA, Inc./ Fujifilm Holdings America Corporation/Fujifilm

3.6    GE Healthcare, Inc./General Electric Company

3.7    Hitachi Aloka Medical America/Hitachi Aloka Medical/ Hitachi Medical/Hitachi

3.8    Hologic, Inc.

3.9    Mammotome/Devicor Medical Products, Inc.

3.10  Mindray Medical USA Corporation/Mindray Medical International LTD

3.11  Philips Healthcare, Inc./Royal Philips NV

3.12  Qiagen NV

3.13  Samsung Medison/Samsung Electronics America, Inc./ Samsung Electronics Co., LTD/Samsung

3.14  Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG

3.15  Toshiba America Medical Systems, Inc./Toshiba Corporation

 

 

APPENDIX:  COMPANY LISTING

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact custcare@informa.com. You can also call 1.908.748.1221 (or toll-free within the U.S. at 1.888.670.8900) or fax 1.646.666.9878.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home